I-MED Surgical has acquired the Canadian rights to distribute OPHTEC ARTISAN and ARTIFLEX refractive phakic intraocular lenses and capsular tension rings.
Online PR News – 05-January-2011 – – 04-Jan-2011 - I-MED Surgical, a division of I-MED Pharma, announced today that it has signed the Canadian rights to market and distribute OPHTEC’s ARTISAN® and ARTIFLEX® phakic intraocular lenses (pIOL) as well as the OPHTEC capsular tension rings (CTR) all of which hold Health Canada Medical Device licences. I-MED Surgical will begin a phased commercial launch of these new lenses and capsular tension rings with full distribution expected by Q1 2011.
The ARTISAN® phakic IOL has passed the test of time by filling the need for those who seek a predictable, reversible and stable solution for the surgical correction of myopia, hyperopia and astigmatism.
The next generation of iris fixated phakic intraocular lenses is heralded by the ARTIFLEX® foldable pIOL. The ARTIFLEX®’s small incision surgery offers better predictability and faster recovery.
“The addition of the OPHTEC refractive surgery products gives Canadian ophthalmologists access to tried and tested solutions for phakic refractive correction,” said Dr. Ilan Hofmann, President, I-MED Pharma. “We are pleased that with the addition of the OPHTEC line, I-MED Surgical now offers the most complete line of IOLs in Canada.”
OPHTEC designs, manufactures, markets and distributes ophthalmic medical devices used in anterior segment surgery. Primary product lines include ARTISAN® and ARTIFLEX™ Phakic intraocular lenses, OPHTEC Capsular Tension Rings, Iris Reconstruction Implants, and a full line of intraocular lenses for cataract surgery. Worldwide marketing and distribution of products is achieved through direct sales and through premium distributorship arrangements.
For more information about the company please visit www.ophtec.com.
I-MED Pharma innovates, manufactures and distributes medical, surgical and veterinary eye care products. I-MED remains uniquely focused on ophthalmology and is divided into three functional business units: Surgical, Pharma and Animal Health Divisions. It researches, develops, manufactures and sources the most effective and advanced solutions to eye disorders like cataracts, refractive surgery, corneal transplants, dry eye, and glaucoma.
For more information please visit www.imedpharma.com.